In this episode, Jake Ghannam, Executive Vice President and Chief Commercial Officer of Insightec, discusses how MR-guided focused ultrasound can expand access to neuroscience care, the strategic case for health systems, and how to build a successful program. This episode is sponsored by Insightec. Statistics and data referenced in this episode can be found at the following sources: 1. Information and stats in this podcast were sourced from the following:Ney JP, Steinmetz JD, Anderson-Benge E, et al. US Burden of Disorders Affecting the Nervous System: From the Global Burden of Disease 2021 Study. JAMA Neurol. 2026;83(1):20-34. doi:10.1001/jamaneurol.2025.4470 2. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov Disord. 2013;28(3):311-318. doi:10.1002/mds.25292 3. Marras, C., Beck, J.C., Bower, J.H. et al. Prevalence of Parkinson’s disease across North America. npj Parkinson's Disease 4, 21 (2018). 4. https://essentialtremor.org/ 5. Pearson C, Hartzman A, Munevar D, et al. Care access and utilization among Medicare beneficiaries living with Parkinson's disease. npj Parkinson’s Dis. 2023;9(1):108. 6. Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(s1):S3-S8. 7. Nicole A. Silva, Ariana Hernandez, Alok K. Dwivedi, Paul Mihas, Daniel A. Roque, Vibhor Krishna; Exploring the Patient Pathway to Focused Ultrasound Ablation for Essential Tremor: A Mixed-Method Approach. Stereotact Funct Neurosurg 2026; https://doi.org/10.1159/000551996 8. https://health.usnews.com/best-hospitals/rankings/neurology-and-neurosurgery (July 2026) 9. Surpassing DBS -Source: Carevoyance & Insightec Data on file 10. *Search: “Premarket Approval (PMA) Database” - https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm o P150038: Essential Tremor Indication o P1550038/S006: Tremor Dominant Parkinson’s Indication o P150038/S014: Idiopathic Parkinson’s Disease (unilateral) Indication o P150038/S037: Idiopathic Parkinson’s Disease (Staged, bilateral) Indication o P150038/S015: Post-approval study (PAS) results from the 5-year follow-up
